Work

First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.5052

Authors: Diletta Bianchini, Aurelius Gabriel Omlin, Carmel Jo Pezaro, Deborah Mukherji, David Lorente Estelles, Andrea Zivi, Roberta Ferraldeschi, Mateus Crespo, Aby Buchbinder, Gerhardt Attard, Howard I. Scher, Johann Sebastian De Bono, Daniel Costin Danila

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Enzon Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601756826

Cites:

Cited by: 5

Related to: 10